Abstract
Small ubiquitin-like modifier (SUMO) modification plays an important regulatory role in T cell receptor (TCR) signaling transduction. SUMO-specific proteases (SENPs) have dual-enzyme activities; they can both process SUMO precursors as endopeptidases and participate in SUMO deconjugation as isopeptidases. It remains unclear how the SUMO system, especially SENP1, is regulated by TCR signaling. Here, we show that Lck phosphorylates tyrosine 270 (Y270) of SENP1 upon TCR stimulation, indicating that SENP1 is a substrate of Lck. In vitro endopeptidase activity analysis showed that mutating SENP1 Y270 to either phenylalanine (F) to mimic the phosphorylation-defective state or to glutamate (E) to mimic the negative charge of tyrosine phosphorylation in the enzyme microenvironment did not change its endopeptidase activity towards pre-SUMO1. However, SENP1 Y270E but not Y270F mutation exhibited decreased endopeptidase activity towards pre-SUMO3. Through in vivo isopeptidase activity analysis by rescue expression of SENP1 and its Y270 mutants in a SENP1 CRISPR knockout T cell line, we found that SENP1 Y270F downregulated its isopeptidase activity towards both SUMO1 and SUMO2/3 conjugation by reducing SENP1 binding with sumoylated targets. While overexpression of SENP1 inhibited TCR-induced IL-2 production, overexpression of SENP1 Y270F enhanced it instead. In summary, TCR-induced Y270 phosphorylation of SENP1 may promote its isopeptidase activity and specifically decrease its endopeptidase activity against pre-SUMO3, which finely tunes activation of T cells.
Introduction
Small ubiquitin-like modifier (SUMO) modification plays important roles in diverse cellular processes by regulation of most cellular signaling pathways. Abnormal sumoylation is related with human diseases, including cancer, neurodegenerative disorders, inflammation, and viral infection (; ; ; ; ; ). There are four mammalian SUMO paralogs: SUMO1, SUMO2, SUMO3, and SUMO4, consisting of 101, 95, 103, and 95 amino acids, respectively. SUMO2 and SUMO3 are nearly identical, only with differences of three amino acids in their mature forms (; ). SUMO1–3 covalently attach to particular lysine residues (often within a consensus site ψKxE/D, where ψ is an amino acid with a large hydrophobic side chain) of target proteins as post-translational modifiers (), whereas the functional role of SUMO4 remains elusive. SUMOs are conjugated to target proteins by forming an isopeptide bond through a multistep enzymatic cascade, which involves a SUMO-activating enzyme E1 (a heterodimer composed of SAE1 and SAE2), a SUMO-conjugating enzyme E2 (Ubc9), and a SUMO E3 ligase (). Major differences among SUMOs comprise not only their expression levels but also their specificities to SUMO-specific proteases (SENPs) and to forming SUMO chains ().
SUMOs are synthesized as inactive precursors and are cleaved by SENPs by removing several amino acids from the C-terminus of pre-SUMOs, with the exception of SUMO4, which contains Pro90 preventing its maturation by SENPs and then sumoylation (). Sumoylation is reversible and highly transient due to the presence of SENPs. SENPs act as both endopeptidases and isopeptidases, and this dual function shows great significance during sumoylation cycle (). SENPs belong to the clan CE of cysteine proteases characterized by an adenain-like catalytic domain (). It consists of SENP1–3 and SENP5–8 in SENP family, although SENP8 exhibits specificity for neddylation (another ubiquitin-like modification) instead of sumoylation (; ).
SENPs share a highly evolutionary conserved catalytic domain in C-terminus, while their variable N-terminal regions result in distinct spatial distributions and even substrate specificities (). SENPs specifically distinguish precursors or conjugates of distinct SUMO paralogs. Hydrolysis of SUMO1–3 precursors by SENP1 can be detected in vitro. Preferring pre-SUMO1 > pre-SUMO2 > pre-SUMO3, SENP1 hydrolyzes SUMO1 precursor in a more efficient way (), whereas SENP2 displays a slight preference for SUMO2 precursor (; ). Besides, SENP1 is indispensable for desumoylation of SUMO1-modified but not of SUMO2/3-modified proteins (). SENP3 and SENP5 preferentially remove SUMO2/3 conjugates from protein substrates (; ). SENP6 and SENP7 are proficient in deconjugating di-SUMO2/3 and poly-SUMO2/3 chains (; ; ).
Sumoylation is important in regulation of T cell receptor (TCR) signaling (; ; ; , ,; ). However, how the SUMO system is regulated by TCR is unclear. Here, we have demonstrated that upon TCR stimulation, Lck phosphorylates tyrosine 270 of SENP1 in its N-terminus, the non-catalytic domain, which in turn fine-tunes the enzyme activity and specificity of SENP1 and ensures appropriate activation of T cells. Therefore, we have revealed that TCR induces phosphorylation of SENP1 and then modifies isopeptidase activity and substrate specificity of SENP1, providing a novel mechanism for meticulous regulation of TCR signaling.
Materials and Methods
Plasmids
The cDNAs encoding SENP1 (NP_001254524.1), Lck (NP_001036236.1), ZAP70 (NP_001365523.1), SUMO1 (NP_003343.1), and SUMO3 (NP_008867.2) were amplified by PCR from Jurkat E6.1 T cell cDNA and cloned into the vectors pcDNA3.1-c-Myc (Invitrogen), YFP-C1 (BD), and pGEX-4T-2 (Sigma-Aldrich), respectively. Specific point mutations of SENP1 were introduced by site-directed mutagenesis with a QuikChange Site-Directed Mutagenesis Kit (Stratagene). Primers are shown in Supplementary Table S1.
Antibodies and Regents
Antibodies to SENP1 (C-12), Lck (3A5), RanGAP1 (C-5), c-Myc (9E10), β-actin (C4), and GAPDH (FL-335) were from Santa Cruz Biotechnology. Antibodies to SENP1 (ab108981), SUMO1 (ab32058), and SUMO2/3 (ab3742) were from Abcam. Antibodies to HA (C29F4) and glutathione S-transferase (GST) were from Cell Signaling Technology. M2 antibody to Flag (F1804) was from Sigma-Aldrich, and 4G10 (05-1050) was from Millipore. Anti-human CD3 (OKT3) and anti-human CD28 (CD28.2) were from eBioscience. Goat anti-mouse IgG (31160) was from Thermo Fisher Scientific. Horseradish peroxidase-conjugated secondary antibodies were from Jackson ImmunoResearch.
Cell Culture, Transfection, and Stimulation
Human leukemia Jurkat T cell line E6.1 cells, TAg cells, JCaM1.6 cells, and SENP1−/− cells were cultured in RPMI 1640 medium (HyClone Logan, UT, United States) supplemented with 10% (vol/vol) fetal bovine serum (FBS, Gibco) and 100 U/ml each of penicillin and streptomycin (Life Technologies) at 37°C and 5% CO2. Cells in a logarithmic growth phase were transfected by nucleofection (Lonza 4D Nucleofector™ system). After transfection, cells were cultured for 48 h before harvest. HEK293T cells were cultured in DMEM (HyClone) containing penicillin, streptomycin, and 10% FBS. Transfections were carried out with PEI (Sigma-Aldrich). For TCR stimulation with antibodies, cells were washed with serum-free RPMI 1640 medium and stimulated with 5 μg/ml anti-CD3 and 2 μg/ml anti-CD28, which were crosslinked with goat anti-mouse IgG (5 μg/ml). For pervanadate treatment, cells were incubated with tyrosine phosphatase inhibitor pervanadate (10 mM) for 20 min before harvest.
Immunoprecipitation and Immunoblotting
After washing with ice-cold PBS, cells were lysed in lysis buffer (1% Nonidet P40, 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, and 5 mM EDTA), supplemented with protease inhibitors (10 μg/ml aprotinin, 10 μg/ml leupeptin, and 1 mM PMSF) and phosphatase inhibitors (5 mM sodium pyrophosphate and 1 mM Na3VO4). After clearance by centrifugation, whole-cell lysates were incubated overnight with 0.6 µg of antibodies, and proteins were immunoprecipitated for an additional 4 h at 4°C with protein G Sepharose beads (GE healthcare) with gentle shaking. Immunoprecipitates were extensively washed five times with lysis buffer and were separated by SDS-PAGE. The immunoprecipitated proteins were transferred onto a PVDF membrane and probed overnight at 4°C with primary antibodies, followed by incubation for 1 h at RT with HRP-conjugated secondary antibodies. Signals were visualized by enhanced chemiluminescence (ECL; GE Healthcare) and were exposed to X-ray film or on the ChemiDoc XRS+ system (Bio-Rad). Densitometry analysis was performed with ImageJ software.
Mass Spectrometry
After immunoprecipitation with SENP1 antibody in Jurkat E6.1 T cells, the immunoprecipitates were resolved by SDS-PAGE. Gel bands of interest were excised and subjected to tryptic digestion. After the desalting procedure, the peptides were analyzed by liquid chromatography-tandem MS. The peptides were analyzed by the LTQ Orbitrap Elite system and EASY-nLC 1000 system (Thermo Fisher Scientific), and then proteins in SENP1 immunoprecipitates were identified with the Protein Discovery software. Mass spectrometry proteomic data from this study are deposited to the ProteomeXchange-PRIDE repository (https://www.ebi.ac.uk/pride/archive/) and assigned the dataset number PXD029720.
CRISPR/Cas9 Gene Editing
LentiCRISPRv2 (one vector system) coexpressing a mammalian codon-optimized Cas9 nuclease along with sgRNA to facilitate editing a SENP1 genomic fragment was transfected in the Jurkat E6.1 T cell line (; ). Then, 48 h after transfection, green fluorescent protein (GFP)-positive cells were sorted on a flow cytometer (BD FACSAria II) and seeded individually into 96-well plates. After extended culture, candidate monoclonal cell lines were selected by screening using western blot. The identifications of SENP1 genome-edited cell line are shown in Figure 5 and Supplementary Figure S3.
GST Pull-Down Assay
GST fusion proteins were expressed in BL21 E. coli cells after induction with IPTG (Sangon Biotech). Bacteria were resuspended in lysis buffer (1× PBS pH 7.4, protease inhibitors, and 1% Triton X-100). Bacterial extracts were sonicated for 10 min and centrifuged. GST fusion proteins were purified from bacterial lysates by incubating with glutathione Sepharose beads (GE Healthcare). The precipitates were washed three times with lysis buffer, then incubated at 4°C overnight with cell lysates from HEK293T cells. Coomassie Brilliant Blue staining was used as loading control.
In Vitro Endopeptidase Activity Assay
In vitro endopeptidase activity assay was achieved as previously described (; ). Briefly, GST-SUMO-GFP (Gs-S-Gf) and SENP1 proteins [wild type (WT) or mutants] were expressed in E. coli BL21 cells and purified. To assay the hydrolysis activity, eluted Gs-S-Gf proteins were incubated in the absence (control) or presence of SENP1 WT or its mutants (immobilized on glutathione Sepharose beads), respectively, and then incubated in assay buffer (150 mM NaCl, 10 mM Tris-HCI, and 10 mM DTT) at 37°C for 20 min and boiled in SDS loading buffer, followed by SDS-PAGE and Coomassie staining to analyze.
In Vitro Isopeptidase Activity Assay
SENP1−/− T cells generated by CRISPR/Cas9 system were lysed in lysis buffer supplemented with 20 mM N-ethylmaleimide (Sigma-Aldrich). After clearance by centrifugation, 1% SDS (vol/vol) was added to the supernatants. Proteins were dissociated by incubation at 90°C for 10 min, followed by dilution (1:10) with ice-cold lysis buffer immediately. Endogenous total RanGAP1 (including RanGAP1 and RanGAP1-SUMO1) was immunoprecipitated from the above lysis buffer at 4°C overnight with anti-RanGAP1 antibody and immobilized on protein G Sepharose beads. After extensive washing with lysis buffer, immunoprecipitated proteins were equally divided into aliquots as reaction substrate, followed by incubation with GST-SENP1 WT or its mutants (immobilized on glutathione Sepharose beads) in reaction buffer (150 mM NaCl, 10 mM Tris-HCI, and 2 mM DTT) at 37°C for 20 min, respectively. The reaction was stopped by adding SDS loading buffer, followed by SDS-PAGE and immunoblotting to analyze.
3D Structure Modeling
The 3D structure of SENP1 (full length, 1–644 aa) was predicted using I-TASSER (https://zhanglab.ccmb.med.umich.edu/I-TASSER/) (; , ). The predicted structures of SENP1 Y270F and Y270E mutation were acquired using Missense 3D (http://missense3d.bc.ic.ac.uk/missense3d/) (). The display of structures and measurement of distances were performed by PyMOL software.
Flow Cytometry
To examine the expression level of SENP1, Jurkat E6.1 and SENP1−/− T cells were collected, washed with 1% FBS in PBS buffer, and then permeabilized (Cytofix/Cytoperm Plus; BD) at 4°C for 20 min, followed by washing with 1% FBS/0.5% saponin in PBS buffer. After being sequentially stained with anti-SENP1 antibody on ice overnight and with cross-adsorbed secondary antibody (Alexa Fluor 647) at 4°C for 1 h, the cells were washed three times and resuspended in 1% FBS in PBS buffer, and then examined by using the CytoFLEX flow cytometer (Beckman).
Real-Time PCR
Total RNA was extracted from Jurkat E6.1 and SENP1−/− T cells using TRIzol reagent (Magen) according to the manufacturer’s protocol. RNA was eluted with RNase-free water and quantified using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific). First-strand cDNA was synthesized by reverse transcription with Hifair III 1st Strand cDNA Synthesis Kit (gDNA digester plus, YEASEN, CHINA). Real-time PCR was run on a LightCycler 480 system (Roche) with Hieff qPCR SYBR Green Master Mix (YEASEN, CHINA) in triplicate. Real-time PCR primers sequences are shown in Supplementary Table S1. The relative quantity of mRNA was normalized with GADPH, using the comparative 2–ΔΔCt method.
Enzyme-Linked Immunosorbent Assay
Jurkat E6.1 T cells transfected with empty vector or YFP-SENP1 WT, Y270F, Y270E, and C603S were stimulated for 24 h with anti-CD3 plus anti-CD28, and the determination of the concentration of IL-2 in cultured supernatants by ELISA was achieved as described (,). Briefly, a 96-well plate was coated with capture antibody to IL-2 at 4°C overnight. After pre-blocking at RT for 1 h, triplicates of standards and samples were then incubated at RT for 2 h in the plate. Incubation with detection antibody to IL-2 at RT for 1 h was done, followed by incubation with avidin-HRP at RT for 30 min. The amount of bound avidin was then assessed with TMB peroxidase that was acidified by 2N H2SO4. The absorbance of each well at 450 and 570 nm was then measured with a spectrophotometric plate reader (BioTek).
Statistical Analysis
Data is representative of three independent experiments. GraphPad Prism 5.0 software was used for graphs and statistical analysis, performed with a two-tailed, unpaired Student’s t-test. For all tests, statistical significance was quantified by p-values. When p-values were below 0.05 (*), 0.01 (**), 0.001 (***), or 0.0001 (****), differences were considered statistically significant. In the figures, p-values are indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, and ns, not significant. Graphs represent mean ± standard error of the mean (SEM).
Results
Lck Associates With SENP1
To investigate whether SENP1 is regulated by TCR signaling, we first analyzed SENP1-associated proteins in T cells. In mass spectrometric analysis, nine peptides of Lck were shown in SENP1-immunoprecipitated complex from Jurkat E6.1 T cells (Figure 1A), and two of them had higher frequencies (Figure 1B), suggesting Lck may interact with SENP1. Coimmunoprecipitation analysis verified the association between overexpressed SENP1 and Lck in HEK293T cells (Figure 1C) and between endogenous SENP1 and Lck in Jurkat E6.1 T cells (Figure 1D).
FIGURE 1
TCR Induces Phosphorylation of SENP1 by Lck
Since Lck is a crucial tyrosine kinase in TCR proximal signaling (), we next tested if SENP1 could be phosphorylated by Lck as a substrate. In HEK293T cells, tyrosine phosphorylation of exogenous SENP1 was detected when SENP1 was coexpressed with Lck, whereas it was undetectable when SENP1 was coexpressed with ZAP70, an important downstream kinase of Lck (Figure 2A). In Jurkat E6.1 T cells, anti-CD3 plus anti-CD28 costimulation induced tyrosine phosphorylation of endogenous SENP1; however, this induced phosphorylation disappeared in Lck-deficient JCaM1.6 cells (Figure 2B). We further cotransfected SENP1 with Lck or its kinase dead mutant (K273R) in HEK293T cells and observed that SENP1 was tyrosine phosphorylated only when cotransfected with Lck WT but not with its K273R mutant (Figure 2C), indicating that the kinase activity of Lck was essential for SENP1 phosphorylation. Together, these results demonstrated that SENP1 could be phosphorylated by tyrosine kinase Lck but not ZAP70.
FIGURE 2
Tyr270 on SENP1 Is the Key Phosphorylation Site by Lck
Regarding phosphorylation sites, Lck has a strong preference for Ile, Leu, or Val at the −1 position, whereas it cannot tolerate Asp at this position, and Lck has a moderate preference for bulky hydrophobic residues at the +3 position (; ). To identify the crucial phosphorylation site on SENP1 by Lck, we checked all tyrosine residues and their −1 and +3 position residues on SENP1 and noticed that four tyrosine residues Tyr119, Tyr194, Tyr270, and Tyr349 are in accordance with the rule of Lck phosphosite preference (Figure 3A). Interestingly, all of them are located in the N-terminal non-catalytic domain of SENP1 (Figure 3B). By mutating tyrosine to phenylalanine, we constructed Y119F, Y194F, Y270F, and Y349F mutants of SENP1, respectively. Through cotransfection of SENP1 YF mutants separately with Lck in HEK293T cells, we examined the effect of each YF mutation on phosphorylation of SENP1 by Lck. We found that Lck-mediated tyrosine phosphorylation of SENP1 remarkably disappeared when mutating Tyr270 to Phe (Figure 3C). Similarly, Y270F mutation notably decreased tyrosine phosphorylation of SENP1 induced by pervanadate (tyrosine phosphatase inhibitor) treatment in Jurkat TAg cells (Figure 3D). However, TCR-induced phosphorylation of SENP1 only reduced modestly with anti-CD3 stimulation (Figure 3E), suggesting that other tyrosine sites of SENP1 may also be phosphorylated upon TCR stimulation. SENP1 Tyr270 was a middle conserved site among various species, as its conservative index is 0.7 in alignment of 58 species in the database of VarSite; meanwhile, SENP1 Tyr270 is completely conserved in primates (Supplementary Figure S1), suggesting Y270 phosphorylation might be related to primate-specific immune responses.
FIGURE 3
SENP1 Y270E Specifically Decreases Its Endopeptidase Activity Towards Pre-SUMO3 In Vitro
Without characteristic features, the N-terminal regions of SENPs presumably control their enzymatic properties intrinsically (). We questioned if SENP1 Y270 phosphorylation could regulate its enzyme activity. Firstly, we assessed the impact of SENP1 Y270 phosphorylation on its endopeptidase activity by an in vitro assay (Figures 4A,B). We fused full-length SUMO1, i.e., precursor with GST at its N-terminus, with GFP at C-terminus to construct the recombinant SUMO1 precursor simultaneously fused with two tags (GST-preSUMO1-GFP or Gs-pS1-Gf, 64 kDa) and used it as a substrate of SENP1 endopeptidase according to the literatures (; ). Proteolytic cleavage of Gs-pS1-Gf by SENP1 yields two products, GST-SUMO1 (GST fused with mature SUMO1, approximately 38 kDa) and GFP moieties (HSTV peptide fused to N-terminus of GFP, about 26 kDa). The ratio of product/substrate reflects the reaction efficiency (; ). As expected, the capability of SENP1 to remove C-terminal GFP moiety from Gs-pS1-Gf was abolished by the catalytic inactive C603S mutation. However, neither a tyrosine phosphorylation-deficient Y270F mutant nor a Y270E mutant (which mimics the negative charge of tyrosine phosphorylation in the enzyme microenvironment) of SENP1 had any impact on its endopeptidase activity towards pre-SUMO1, indicating that Y270 phosphorylation on SENP1 did not regulate its endopeptidase activity towards pre-SUMO1.
FIGURE 4
Since SENP1 prefers pre-SUMO1 > pre-SUMO2 > pre-SUMO3, we guessed that SENP1 Y270 phosphorylation might also not affect its endopeptidase activity towards pre-SUMO2 or pre-SUMO3. We further performed an in vitro assay against SUMO3 precursor Gs-pS3-Gf (; ). Due to the substrate preference of SENP1 endopeptidase activity, the bands related to GST-SUMO3 were faint. Unlike Gs-pS1-Gf, there was a band near above 25 kDa in all lanes when using Gs-pS3-Gf even in the absence of GST-SENP1 (labelled with GFP/GST in Figure 4B). Western blot showed that the Gs-pS3-Gf protein could be cleaved to generate GST-tag protein for uncertain reason (Supplementary Figure S2); thus, the band near above 25 kDa contained mixed proteins of GFP moiety (VPESSLAGHSF peptide fused to the N-terminus of GFP) and GST-tag. Nevertheless, we performed endopeptidase activity assay towards pre-SUMO3 with Coomassie staining and immunoblotting at the same time (Figures 4B,C). As expected, GST-SUMO3 could not be detected when reacting with SENP1 C603S mutant. Interestingly, GST-SUMO3 could not also be detected when reacting with SENP1 Y270E mutant, suggesting that SENP1 Y270E specifically decreases its hydrolytic ability to SUMO3 precursor.
The above data indicates that tyrosine phosphorylation on Y270 of SENP1 may modulate its endopeptidase activity with selectivity, which has no effects on its endopeptidase capacity toward pre-SUMO1, but decreases its endopeptidase activity against pre-SUMO3.
SENP1 Y270 Phosphorylation Influences Its Isopeptidase Activity Both In Vivo and In Vitro
Next, we examined whether SENP1 Y270 phosphorylation could influence its isopeptidase activity. Considering that the presence of endogenous SENP1 may interfere with the effects of ectopic-expressed SENP1, we set to construct a SENP1−/− T cell line by CRISPR/Cas9 system. The genome sequencing and western blot results showed that the expression of CRISPR/Cas9-gRNA targeting the first exon of SENP1 induced a thymidine nucleotide insertion in SENP1 locus to knockout SENP1 gene (Figures 5A,B; Supplementary Figures S3A,B).
FIGURE 5
Expectedly, SENP1−/− T cells displayed much stronger SUMO1 and SUMO2/3 modification (Supplementary Figure S3C). By checking the mRNA expression of SENP2 (another sub-family member of SENP1) in SENP1−/− T cells, we found that SENP1 knockout did not affect the transcription of SENP2 (Supplementary Figure S3D), and western blot showed that the expressions of TCR proximal signaling proteins were not affected in SENP1−/− T cells (Supplementary Figure S3E). Therefore, the increased sumoylation in SENP1−/− T cells should be the direct result of SENP1 knockout. Global sumoylation reflects the isopeptidase activity of SENP1; hence, we performed an in vivo SUMO1-profiling assay in this SENP1 knockout cell line to assess the impact of SENP1 Y270 phosphorylation on its isopeptidase activity (Figure 5C). As expected, SENP1 WT overexpression efficiently reduced the overall sumoylation of cellular proteins, and the capability of SENP1 to remove SUMO1 conjugates from protein substrates was abolished by C603S mutation. Compared with SENP1 WT, the Y270F mutation obviously decreased its desumoylation activity, although this decrease was less than that caused by C603S mutation (Figure 5C), indicating that Y270 tyrosine phosphorylation contributed to the isopeptidase activity of SENP1. Interestingly, the Y270E negative charge mimic mutation did not increase the desumoylation activity of SENP1 but only showed similar isopeptidase activity to SENP1 WT in vivo (Figure 5C). A similar pattern of desumoylation activities of SENP1 WT and its mutants is shown in Figure 5D, when analyzing their activities by the ratio of RanGAP1-SUMO1/RanGAP1 in SENP1−/− T cells with rescue expression of YFP-SENP1 or its mutants (Figure 5D). Considering the similar activities between SENP1 WT and Y270E mutant, we guessed that in T cells, SENP1 Y270E mutant did not show a stronger activity than SENP1 WT that might result from a certain degree of constitutive Y270 phosphorylation of SENP1 WT. To exclude the possible influence of basal phosphorylation on SENP1, we performed an in vitro isopeptidase activity assay, in which E. coli recombinant GST fusion proteins of SENP1 WT (which could not be phosphorylated) and its mutants were incubated with immunoprecipitated endogenous total RanGAP1 (including RanGAP1 and RanGAP1-SUMO1) from SENP1−/− T cells, respectively (Figure 5E). Basing on the ratio of RanGAP1-SUMO1/RanGAP1, we observed that the desumoylation activity of SENP1 was decreased by both Y270F and C603S mutations, but was increased by Y270E mutation (Figure 5E), indicating Y270 phosphorylation could increase SENP1 isopeptidase activity. Similar results from in vivo SUMO2/3-profiling assay also suggested that SENP1 Y270 phosphorylation influenced its isopeptidase activity (Figure 5F). Combining the above in vivo and in vitro results, we conclude that Y270 phosphorylation is required for the optimal isopeptidase activity of SENP1.
In T cells, SENP1 overexpression inhibits TCR-induced IL-2 production (). Thus, we further examined the effects of Y270 phosphorylation on TCR-induced IL-2 production in Jurkat E6.1 T cells by ELISA (Figure 5G). Consistently, TCR-induced IL-2 production was inhibited by overexpression of SENP1 WT and was increased by C603S mutation, confirming that desumoylation is overall a negative factor in T cell activation. Meanwhile, the IL-2 production was enhanced by Y270F mutation and inhibited by Y270E mutation (Figure 5G), aligned with their desumoylation effects (Figures 5C–F).
SENP1 Y270 Phosphorylation Influences Its Binding Propensity for Substrates
We next investigated how Y270 phosphorylation regulated SENP1 isopeptidase activity. Firstly, we analyzed whether SENP1 Y270 phosphorylation could directly change its protein conformation, especially the catalytic core domain, to regulate its enzyme activity. The predicted structures of SENP1 WT (1–644 aa), Y270F, and Y270E mutation were obtained, and His533, Asp550, and Cys603 formed the catalytic triad (Figure 6A). We measured the distances between these key residues in these structures and found that neither Y270F nor Y270E mutation brought obvious changes to it (Figure 6B). Since the binding of SUMO1 β-grasp domain (residues 20–92) induces structural changes in the active site of SENP1 and then enhances the enzyme activity of SENP1 (; ), the binding of SUMO to SENP1 is hence a prerequisite for SENP1 isopeptidase activity, and we wondered whether Y270 phosphorylation on SENP1 could regulate its isopeptidase activity via modulating its binding to SUMO-conjugated substrates. We performed the GST pull-down assay by using GST fused to the N-terminus of mature SUMO1 (1–97 aa) or SUMO3 (1–92 aa). Y270F mutation reduced SENP1 binding to both GST-SUMO1 and -SUMO3. In contrast, Y270E mutation increased its binding to both (Figures 6C,D). These results indicated that Y270 phosphorylation may increase the binding propensity between SENP1 and sumoylated proteins, which can in turn enhance the isopeptidase activity of SENP1. We supposed that allosteric activation of SENP1 by SUMO1 may bring residue 270 closer to SUMO in space, and Y270 phosphorylation may stabilize and enhance the binding between SENP1 and SUMO, which could lead to more efficient desumoylation of the substrates.
FIGURE 6
Discussion
Sumoylation plays important roles in the regulation of many cellular events. However, how the SUMO system, especially SUMO-specific proteases, is regulated by receptor signaling, such as TCR signaling, remains unclear. In this study, we have found that SENP1 associates with Lck and TCR stimulation induces SENP1 Y270 phosphorylation via Lck. This phosphorylation specifically decreases SENP1 endopeptidase activity towards pre-SUMO3 in vitro and promotes SENP1 isopeptidase activity by enhancing its binding with both SUMO1- and SUMO2/3-conjugated substrates. Moreover, SENP1 Y270 phosphorylation plays an important regulatory role in T cell activation through reduced overall sumoylation and subsequent inhibition of T cell response. In summary, this study provides the first evidence that TCR signaling could directly phosphorylate SENP1 to modify its enzyme activity and specificity, facilitating fine-tuning of T cell response through balancing the equilibrium between cellular sumoylation and desumoylation (Figure 7).
FIGURE 7
The N-terminus of SENP1 mainly contributes to SUMO paralogue specificity, and the catalytic core domain of SENP1 is located in its C-terminus (; ). SENP1 has been reported to display little specificity in its isopeptidase activity towards different SUMO-conjugated substrates in vitro () and prefers to deconjugate SUMO1- than SUMO2/3-modified substrates in the mouse embryo (). We have revealed here that in Jurkat T cells, SENP1 could efficiently deconjugate both SUMO1- and SUMO2/3-conjugated substrates, respectively, and SENP1 Y270 phosphorylation enhances its isopeptidase activity towards both via increasing its binding propensity to them. Our finding that the non-preference of SENP1 for SUMO1- or SUMO2/3-conjugated substrates may have been caused by the cell types used or overexpression of SENP1 in our experiments. We also observed an interesting result that SENP1 Y270F or Y270E mutants displayed a much clearer phosphorylation effect of SENP1 on RanGAP1-SUMO1 deconjugation in vitro than in vivo (Figures 5D,E), in line with the findings that SENP1 could deconjugate sumoylated RanGAP1 in vitro but not in vivo (; ), which has been explained as sumoylated RanGAP1 may be protected from SENP1 in vivo for being an integral part of the RanBP2 E3 ligase complex (; ). Together, our findings have revealed that tyrosine phosphorylation on SENP1 Y270 has a critical role in the regulation of SENP1 isopeptidase activity through increasing its binding propensity with sumoylated proteins.
SENPs also hydrolyzes SUMO precursors in addition to deconjugating sumoylated proteins. Preferring pre-SUMO1 > pre-SUMO2 > pre-SUMO3, SENP1 hydrolyzes SUMO1 precursor in a more efficient way (). The N-terminus helps to achieve this specificity; however, the detailed mechanism is unclear (). We have discovered that Y270 phosphorylation does not affect SENP1 hydrolyzing pre-SUMO1, but, unexpectedly, decreases its hydrolyzing activity towards pre-SUMO3. This finding supplies a regulatory mechanism underlying SENP1 endopeptidase specificity that Y270 phosphorylation of SENP1 could make it focus more on hydrolyzing pre-SUMO1 through weakening its endopeptidase activity towards pre-SUMO3, thereby strengthening its specificity.
Phosphorylation plays important roles in regulation of SENP localization, turn over, and isopeptidase activity. Disturbed blood flow induces SENP2 phosphorylation and promotes its nuclear export in epithelial cells (); mTOR kinase phosphorylates several N-terminal serine/threonine of SENP3 to promote the nucleolar targeting of SENP3 to facilitate ribosome maturation (; ); tumor suppressor protein p19 (Arf) triggers SENP3 to be phosphorylated and then polyubiquitinated and degraded (). In mitosis, phosphorylation of SENP3 may regulate its enzyme activity and spindle localization (). The C-terminal phosphorylation of yeast SUMO isopeptidase Ulp2 during mitosis may inhibit its isopeptidase activity (). Cdk1-mediated Ser/Thr phosphorylation in the N-terminal region of SENP3 in mitotic cells downregulates its deconjugation activity towards topoisomerase TopoIIa through decreasing its interaction with it (; ). Different from the above Ser/Thr phosphorylation of SENPs, our study has demonstrated for the first time that in TCR signaling, Lck-mediated tyrosine phosphorylation at SENP1 Y270 regulates the binding propensity between SENP1 and the SUMO-conjugated substrate and then increases SENP1 isopeptidase activity, while blocking the endopeptidase activity towards pre-SUMO3 but not pre-SUMO1 and in turn enhancing SENP1 peptidase specificity. Similar mechanisms for other SENPs in which the enzyme activity and specificity could be modulated by tyrosine phosphorylation in receptor signaling may also exist.
Evolutionary conservation analysis has shown that the Y270 is highly conserved in different species of primates, but not in rodents (Supplementary Figure S1). Guinea pigs (Cavia porcellus) has a conserved tyrosine to Y270 in SENP1, but mice and rats do not. Due to the effect of Y270 phosphorylation on SENP1 activity and then T cell activation, it is rational to doubt that Y270 might contribute to different immune characteristics of different species of rodents. It has been revealed that there is greater similarity between humans and guinea pigs than rats or mice in many immunological responses, because guinea pigs and humans are more homologous in some immune-related proteins (). From the perspective of evolutionary conservation, we infer that this phosphorylation-regulated enzyme activity of SENP1 might closely correlate with certain types of immune responses. Further investigations and evidence are needed in the future.
In summary, our findings reveal how SENP1 is regulated by TCR signaling and how Y270 phosphorylation on SENP1 modulates its enzyme activity and specificity and thereby finely tunes the activation of T cells. This study provides a different angle to understand T cell immunology and SENP1 regulation and implies a novel regulatory relationship between receptor signaling and SUMO system (, , ).
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material; The mass spectrometry proteomic data presented in the study are deposited in the ProteomeXchange-PRIDE repository, accession number PXD029720 further inquiries can be directed to the corresponding author.
Author contributions
YL conceived and supervised this study. Y-YL designed the experiments. Y-YL, HC, B-NG, SM, Q-LW, and SM performed the experiments. Y-YL and YL analyzed the data and wrote the manuscript. YL, B-NG and Y-YL edited the manuscript.
Funding
This study was supported by the National Natural Science Foundation of China (32170889), the Guangdong Provincial Natural Science Foundation (2021A1515010543), and the Guangdong Science and Technology Department (2020B1212060031).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.789348/full#supplementary-material
Supplementary Figure S1Evolutionary conservation analysis of SENP1 Y270 by amino acid sequence alignment of different species.
Supplementary Figure S2Immunoblotting of purified GST-SUMO3-GFP protein. Purified GST-pSUMO3-GFP protein was incubated with or without GST-SENP1 in endopeptidase activity assay in vitro, followed by SDS-PAGE and immunoblotting with anti-GFP (left) and anti-GST (right) antibody.
Supplementary Figure S3The information of SENP1 knockout cell line. (A) The guide sequence targeting the first exon of SENP1.(B) Flow cytometry analysis of SENP1 knockout in WT and SENP1−/− T cells. (C) The levels of total SUMO1 and SUMO2/3 modification in WT and SENP1−/− T cells examined by immunoblot. Actin was blotted as loading control. (D) The mRNA expression levels of SENP2 in WT and SENP1−/− T cells were analyzed by quantitative real-time PCR. (E) The expression levels of TCR proximal signaling proteins in WT and SENP1−/− T cells. Cells were lysed and then analyzed for the expression level of endogenous proteins Lck, ZAP70, LAT, PLCγ1, PKCθ, and SLP76 by western blot. GAPDH was blotted as loading control.
References
1
AlegreK. O.ReverterD. (2011). Swapping Small Ubiquitin-like Modifier (SUMO) Isoform Specificity of SUMO Proteases SENP6 and SENP7. J. Biol. Chem.286 (41), 36142–36151. 10.1074/jbc.M111.268847
2
BaileyD.O'HareP. (2004). Characterization of the Localization and Proteolytic Activity of the SUMO-specific Protease, SENP1. J. Biol. Chem.279 (1), 692–703. 10.1074/jbc.M306195200
3
BaldwinM. L.JuliusJ. A.TangX.WangY.BachantJ. (2009). The Yeast SUMO Isopeptidase Smt4/Ulp2 and the polo Kinase Cdc5 Act in an Opposing Fashion to Regulate Sumoylation in Mitosis and Cohesion at Centromeres. Cell Cycle8 (20), 3406–3419. 10.4161/cc.8.20.9911
4
BrownlieR. J.ZamoyskaR. (2013). T Cell Receptor Signalling Networks: Branched, Diversified and Bounded. Nat. Rev. Immunol.13 (4), 257–269. 10.1038/nri3403
5
ChangH.-M.YehE. T. H. (2020). SUMO: From Bench to Bedside. Physiol. Rev.100 (4), 1599–1619. 10.1152/physrev.00025.2019
6
ChenC.-H.NamanjaA. T.ChenY. (2014). Conformational Flexibility and Changes Underlying Activation of the SUMO-specific Protease SENP1 by Remote Substrate Binding. Nat. Commun.5, 4968. 10.1038/ncomms5968
7
CretonS.JentschS. (2010). SnapShot: The SUMO System. Cell143 (5), 848. 10.1016/j.cell.2010.11.026
8
DingX.WangA.MaX.DemarqueM.JinW.XinH.et al (2016). Protein SUMOylation Is Required for Regulatory T Cell Expansion and Function. Cel Rep.16 (4), 1055–1066. 10.1016/j.celrep.2016.06.056
9
FlothoA.MelchiorF. (2013). Sumoylation: A Regulatory Protein Modification in Health and Disease. Annu. Rev. Biochem.82, 357–385. 10.1146/annurev-biochem-061909-093311
10
Geiss-FriedlanderR.MelchiorF. (2007). Concepts in Sumoylation: A Decade on. Nat. Rev. Mol. Cel Biol8 (12), 947–956. 10.1038/nrm2293
11
GongL.MillasS.MaulG. G.YehE. T. H. (2000). Differential Regulation of Sentrinized Proteins by a Novel Sentrin-specific Protease. J. Biol. Chem.275 (5), 3355–3359. 10.1074/jbc.275.5.3355
12
GongL.YehE. T. H. (2006). Characterization of a Family of Nucleolar SUMO-specific Proteases with Preference for SUMO-2 or SUMO-3. J. Biol. Chem.281 (23), 15869–15877. 10.1074/jbc.M511658200
13
Guerra de SouzaA. C.PredigerR. D.CimarostiH. (2016). SUMO-Regulated Mitochondrial Function in Parkinson's Disease. J. Neurochem.137 (5), 673–686. 10.1111/jnc.13599
14
GuoJ.ZhouH.-X. (2016). Allosteric Activation of SENP1 by SUMO1 β-grasp Domain Involves a Dock-And-Coalesce Mechanism. eLife5, e18249. 10.7554/eLife.18249
15
HaindlM.HarasimT.EickD.MullerS. (2008). The Nucleolar SUMO-specific Protease SENP3 Reverses SUMO Modification of Nucleophosmin and Is Required for rRNA Processing. EMBO Rep.9 (3), 273–279. 10.1038/embor.2008.3
16
HeY.YangZ.ZhaoC.-s.XiaoZ.GongY.LiY.-Y.et al (2021). T-cell Receptor (TCR) Signaling Promotes the Assembly of RanBP2/RanGAP1-SUMO1/Ubc9 Nuclear Pore Subcomplex via PKC-θ-Mediated Phosphorylation of RanGAP1. eLife10, e67123. 10.7554/eLife.67123
17
HeoK.-S.LeN.-T.CushmanH. J.GiancursioC. J.ChangE.WooC.-H.et al (2015). Disturbed Flow-Activated p90RSK Kinase Accelerates Atherosclerosis by Inhibiting SENP2 Function. J. Clin. Invest.125 (3), 1299–1310. 10.1172/JCI76453
18
HickeyC. M.WilsonN. R.HochstrasserM. (2012). Function and Regulation of SUMO Proteases. Nat. Rev. Mol. Cel Biol13 (12), 755–766. 10.1038/nrm3478
19
IttisoponpisanS.IslamS. A.KhannaT.AlhuzimiE.DavidA.SternbergM. J. E. (2019). Can Predicted Protein 3D Structures Provide Reliable Insights into whether Missense Variants Are Disease Associated?. J. Mol. Biol.431 (11), 2197–2212. 10.1016/j.jmb.2019.04.009
20
JohnsonE. S. (2004). Protein Modification by SUMO. Annu. Rev. Biochem.73, 355–382. 10.1146/annurev.biochem.73.011303.074118
21
KarhausenJ.UlloaL.YangW. (2021). SUMOylation Connects Cell Stress Responses and Inflammatory Control: Lessons from the Gut as a Model Organ. Front. Immunol.12, 646633. 10.3389/fimmu.2021.646633
22
KimJ. H.BaekS. H. (2009). Emerging Roles of Desumoylating Enzymes. Biochim. Biophys. Acta (Bba) - Mol. Basis Dis.1792 (3), 155–162. 10.1016/j.bbadis.2008.12.008
23
KleinU. R.HaindlM.NiggE. A.MullerS. (2009). RanBP2 and SENP3 Function in a Mitotic SUMO2/3 Conjugation-Deconjugation Cycle on Borealin. Mol. Biol. Cel20 (1), 410–418. 10.1091/mbc.e08-05-0511
24
KunzK.PillerT.MüllerS. (2018). SUMO-specific Proteases and Isopeptidases of the SENP Family at a Glance. J. Cel Sci.131 (6), jcs211904. 10.1242/jcs.211904
25
KuoM.-L.den BestenW.ThomasM. C.SherrC. J. (2008). Arf-induced Turnover of the Nucleolar Nucleophosmin-Associated SUMO-2/3 Protease Senp3. Cell Cycle7 (21), 3378–3387. 10.4161/cc.7.21.6930
26
LimaC. D.ReverterD. (2008). Structure of the Human SENP7 Catalytic Domain and Poly-SUMO Deconjugation Activities for SENP6 and SENP7. J. Biol. Chem.283 (46), 32045–32055. 10.1074/jbc.M805655200
27
LiuB.ShuaiK. (2009). Summon SUMO to Wrestle with Inflammation. Mol. Cel35 (6), 731–732. 10.1016/j.molcel.2009.09.002
28
LiuH.SchneiderH.RecinoA.RichardsonC.GoldbergM. W.RuddC. E. (2015). The Immune Adaptor SLP-76 Binds to SUMO-RANGAP1 at Nuclear Pore Complex Filaments to Regulate Nuclear Import of Transcription Factors in T Cells. Mol. Cel59 (5), 840–849. 10.1016/j.molcel.2015.07.015
29
MaduI. G.ChenY. (2012). Assays for Investigating deSUMOylation Enzymes. Curr. Protoc. Mol. Biol.99, t10–t30. 10.1002/0471142727.mb1030s99
30
MaduI. G.NamanjaA. T.SuY.WongS.LiY.-J.ChenY. (2013). Identification and Characterization of a New Chemotype of Noncovalent SENP Inhibitors. ACS Chem. Biol.8 (7), 1435–1441. 10.1021/cb400177q
31
MendlerL.BraunT.MüllerS. (2016). The Ubiquitin-like SUMO System and Heart Function. Circ. Res.118 (1), 132–144. 10.1161/CIRCRESAHA.115.307730
32
MikolajczykJ.DragM.BékésM.CaoJ. T.RonaiZ. e.SalvesenG. S. (2007). Small Ubiquitin-Related Modifier (SUMO)-specific Proteases. J. Biol. Chem.282 (36), 26217–26224. 10.1074/jbc.M702444200
33
NayakA.MüllerS. (2014). SUMO-specific Proteases/isopeptidases: SENPs and beyond. Genome Biol.15 (7), 422. 10.1186/s13059-014-0422-2
34
OwerbachD.McKayE. M.YehE. T. H.GabbayK. H.BohrenK. M. (2005). A Proline-90 Residue Unique to SUMO-4 Prevents Maturation and Sumoylation. Biochem. Biophysical Res. Commun.337 (2), 517–520. 10.1016/j.bbrc.2005.09.090
35
Padilla-CarlinD. J.McMurrayD. N.HickeyA. J. (2008). The guinea Pig as a Model of Infectious Diseases. Comp. Med.58 (4), 324–340.
36
RamanN.NayakA.MullerS. (2014). MTOR Signaling Regulates Nucleolar Targeting of the SUMO-specific Isopeptidase SENP3. Mol. Cel. Biol.34 (24), 4474–4484. 10.1128/MCB.00801-14
37
ReverterD.LimaC. D. (2004). A Basis for SUMO Protease Specificity provided by Analysis of Human Senp2 and a Senp2-SUMO Complex. Structure12 (8), 1519–1531. 10.1016/j.str.2004.05.023
38
ReverterD.LimaC. D. (2006). Structural Basis for SENP2 Protease Interactions with SUMO Precursors and Conjugated Substrates. Nat. Struct. Mol. Biol.13 (12), 1060–1068. 10.1038/nsmb1168
39
RoyA.KucukuralA.ZhangY. (2010). I-TASSER: A Unified Platform for Automated Protein Structure and Function Prediction. Nat. Protoc.5 (4), 725–738. 10.1038/nprot.2010.5
40
SanjanaN. E.ShalemO.ZhangF. (2014). Improved Vectors and Genome-wide Libraries for CRISPR Screening. Nat. Methods11 (8), 783–784. 10.1038/nmeth.3047
41
SeelerJ.-S.DejeanA. (2017). SUMO and the Robustness of Cancer. Nat. Rev. Cancer17 (3), 184–197. 10.1038/nrc.2016.143
42
ShahN. H.LöbelM.WeissA.KuriyanJ. (2018). Fine-tuning of Substrate Preferences of the Src-Family Kinase Lck Revealed through a High-Throughput Specificity Screen. eLife7, e35190. 10.7554/eLife.35190
43
ShahN. H.WangQ.YanQ.KarandurD.KadlecekT. A.FallaheeI. R.et al (2016). An Electrostatic Selection Mechanism Controls Sequential Kinase Signaling Downstream of the T Cell Receptor. eLife5, e20105. 10.7554/eLife.20105
44
ShalemO.SanjanaN. E.HartenianE.ShiX.ScottD. A.MikkelsenT. S.et al (2014). Genome-scale CRISPR-Cas9 Knockout Screening in Human Cells. Science343 (6166), 84–87. 10.1126/science.1247005
45
SharmaP.YamadaS.LualdiM.DassoM.KuehnM. R. (2013). Senp1 Is Essential for Desumoylating Sumo1-Modified Proteins but Dispensable for Sumo2 and Sumo3 Deconjugation in the Mouse Embryo. Cel Rep.3 (5), 1640–1650. 10.1016/j.celrep.2013.04.016
46
ShenL. N.DongC.LiuH.NaismithJ. H.HayR. T. (2006). The Structure of SENP1-SUMO-2 Complex Suggests a Structural Basis for Discrimination between SUMO Paralogues during Processing. Biochem. J.397 (2), 279–288. 10.1042/BJ20052030
47
ShenL. N.GeoffroyM.-C.JaffrayE. G.HayR. T. (2009). Characterization of SENP7, a SUMO-2/3-specific Isopeptidase. Biochem. J.421 (2), 223–230. 10.1042/BJ20090246
48
WangQ.-L.LiangJ.-Q.GongB.-N.XieJ.-J.YiY.-T.LanX.et al (2019). T Cell Receptor (TCR)-Induced PLC-Γ1 Sumoylation via PIASxβ and PIAS3 SUMO E3 Ligases Regulates the Microcluster Assembly and Physiological Function of PLC-Γ1. Front. Immunol.10, 314. 10.3389/fimmu.2019.00314
49
WangX.-D.GongY.ChenZ.-L.GongB.-N.XieJ.-J.ZhongC.-Q.et al (2015). TCR-induced Sumoylation of the Kinase PKC-θ Controls T Cell Synapse Organization and T Cell Activation. Nat. Immunol.16 (11), 1195–1203. 10.1038/ni.3259
50
WangY.TianJ.HuangC.MaJ.HuG.ChenY.et al (2020). P53 Suppresses SENP3 Phosphorylation to Mediate G2 Checkpoint. Cell Discov6, 21. 10.1038/s41421-020-0154-2
51
WeiB.HuangC.LiuB.WangY.XiaN.FanQ.et al (2018). Mitotic Phosphorylation of SENP3 Regulates DeSUMOylation of Chromosome-Associated Proteins and Chromosome Stability. Cancer Res.78 (9), 2171–2178. 10.1158/0008-5472.CAN-17-2288
52
WernerA.FlothoA.MelchiorF. (2012). The RanBP2/RanGAP1*SUMO1/Ubc9 Complex Is a Multisubunit SUMO E3 Ligase. Mol. Cel46 (3), 287–298. 10.1016/j.molcel.2012.02.017
53
XiongY.YiY.WangY.YangN.RuddC. E.LiuH. (2019). Ubc9 Interacts with and SUMOylates the TCR Adaptor SLP-76 for NFAT Transcription in T Cells. J. Immunol.203 (11), 3023–3036. 10.4049/jimmunol.1900556
54
XuZ.AuS. W. N. (2005). Mapping Residues of SUMO Precursors Essential in Differential Maturation by SUMO-specific Protease, SENP1. Biochem. J.386 (Pt 2), 325–330. 10.1042/BJ20041210
55
XuZ.ChauS. F.LamK. H.ChanH. Y.NgT. B.AuS. W. N. (2006). Crystal Structure of the SENP1 Mutant C603S-SUMO Complex Reveals the Hydrolytic Mechanism of SUMO-specific Protease. Biochem. J.398 (3), 345–352. 10.1042/BJ20060526
56
YangJ.YanR.RoyA.XuD.PoissonJ.ZhangY. (2015). The I-TASSER Suite: Protein Structure and Function Prediction. Nat. Methods12 (1), 7–8. 10.1038/nmeth.3213
57
YangJ.ZhangY. (2015). I-TASSER Server: New Development for Protein Structure and Function Predictions. Nucleic Acids Res.43 (W1), W174–W181. 10.1093/nar/gkv342
58
ZhaoX. (2018). SUMO-mediated Regulation of Nuclear Functions and Signaling Processes. Mol. Cel71 (3), 409–418. 10.1016/j.molcel.2018.07.027
Summary
Keywords
TCR signaling, Lck kinase, tyrosine phosphorylation of SENP1, isopeptidase activity, endopeptidase specificity
Citation
Li Y-Y, Cen H, Gong B-N, Mai S, Wang Q-L, Mou S and Li Y (2022) TCR-Induced Tyrosine Phosphorylation at Tyr270 of SUMO Protease SENP1 by Lck Modulates SENP1 Enzyme Activity and Specificity. Front. Cell Dev. Biol. 9:789348. doi: 10.3389/fcell.2021.789348
Received
04 October 2021
Accepted
13 December 2021
Published
02 February 2022
Volume
9 - 2021
Edited by
Manoj B. Menon, Indian Institute of Technology Delhi, India
Reviewed by
Sujeet Kumar, Amity University, Mumbai, India
Mariarita Bertoldi, University of Verona, Italy
Updates
Copyright
© 2022 Li, Cen, Gong, Mai, Wang, Mou and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yingqiu Li, lsslyq@mail.sysu.edu.cn
This article was submitted to Signaling, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.